ABSCI CORP (ABSI)
(Delayed Data from NSDQ)
$2.61 USD
-0.08 (-2.97%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $2.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Absci Corporation has a PEG ratio of 6.75 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.09.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ABSI 2.61 -0.08(-2.97%)
Will ABSI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ABSI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABSI
Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates
SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
ABSI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy?
Amgen (AMGN) Beats Q2 Earnings and Revenue Estimates
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates
Other News for ABSI
Calm After Storm appears for ABSI after 5.49% move
Is ABSI primed for upward momentum? 20 Day Moving Average Support shows up after tumbling 5.56%
Is ABSI ready to make a move? Calm After Storm shows up after climbing 3.05%
Absci Corporation: ABS-101 Has Both First-Gen And Next-Gen Competitors
20 Day Moving Average Support appears for ABSI after 2.75% move